What’s Hot Besides Acer Therapeutics Inc. (ACER) Stock?

If you’re on the hunt for stocks to watch today, Acer Therapeutics Inc. (NASDAQ:ACER) is a stock to give close attention to. The company shares are trading 9.52% or 0.22 points down from last closing price of $2.31, reaching $2.09 at last check. The ACER share price has dropped in 5 of the last 5 days and is down -87.76% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -37,481 shares, and in total 58419 shares valued at $122096 were seen changing hands compared with 95900 shares valued at $221529 recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the ACER stock is near its bottom.

Acer Therapeutics Inc. (ACER) shares have notched a 3-month decline of about -87.76%, but has still tumbled -87.82% year to date. By comparison, the stock sank -91.22% over the past 12 months, while it slipped -25.76% over the 1 month. The company’s market cap is around $26.88M, with its short interest ratio standing at 3.48%.

In the current trading session for ACER, the stock witnessed two major price actions, it rose to a high of $2.38 and was down as much as $2.08 at one point. The high recorded is very low when compared to their 52-week high which is $2.2. The 52-week high is now at -93.9 distance from current price. Their recent low of $34.1 represents a -5.45% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for ACER is $8, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

The company recorded an interesting insider purchase transaction by the Director on Jul 03, 2019. A Securities and Exchanges Commission filings show that Steve Aselage bought a total of 5,000 ACER shares that day for a sum of around $18,600. Acer Therapeutics Inc. (ACER) insiders have acquired 5,000 shares in the stock within the past three months. In total, individual insiders traded 5,000 shares in the business, which makes up 35.714% of 14,000 shares that were traded over a year. In the past 12 months, insiders have purchased 14,000 shares while the seller parted with shares.

ACER‘s last price was down -88.8% as compared to the average trading price of 50 days recorded at $18.66 while enlarging the period to 200 trading days, the average closing price was $7.39. At present, there are 10.97 million in the total number of common shares owned by the public and among those 7.48 million shares have been available to trade. The percentage of shares being held by the company management was 0.3% while institutions stake was 61%. The company has generated negative returns on equity over the last 12 months (-67.4%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the ACER stock, there is another set of technicals that should be looked into and considered. Its -24.45% decline from moving average of $2.77 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of 1.57 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of Acer Therapeutics Inc. — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 3 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $31 on shares of Acer Therapeutics Inc. (NASDAQ:ACER), which corresponds to 1,271.68% upside potential than its current market price of $2.09 and implies potential despite the recent drop in the price. However, their current target price has fallen from $31 a month ago and is down handily from the consensus target of $47.6667 a quarter ago.

In the last five years, the EPS of the company has been roughly 52.6%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.

Let’s briefly check the hedge fund interest towards ACER stock. Vanguard Group Inc. added position in the company after it grew 5.4% or 263,722 shares of its common stock. The hedge fund now owns 277,963 shares worth $580,943, SEC documents show. BlackRock Inc. shored up assets in the stock as 19963.45 shares have been purchased, increasing its stake by 1560.8% to 331,553 shares which are currently valued at $692,946. In addition, Northern Trust Corp recently reported that it now owns 48,313 shares making a total of $100,974 based on the recent price. This refelects a change of 24.4% in their ownership.